PortalPublikationenHigh tissue density of FOXP3+ T cells is associated with cli...

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

Standard

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. / Flammiger, Anna; Weisbach, Lars; Huland, Hartwig; Tennstedt, Pierre; Simon, Ronald; Minner, Sarah; Bokemeyer, Carsten; Sauter, Guido; Schlomm, Thorsten; Trepel, Martin.

in: EUR J CANCER, Jahrgang 49, Nr. 6, 01.04.2013, S. 1273-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Flammiger, A, Weisbach, L, Huland, H, Tennstedt, P, Simon, R, Minner, S, Bokemeyer, C, Sauter, G, Schlomm, T & Trepel, M 2013, 'High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer', EUR J CANCER, Jg. 49, Nr. 6, S. 1273-9. https://doi.org/10.1016/j.ejca.2012.11.035

APA

Flammiger, A., Weisbach, L., Huland, H., Tennstedt, P., Simon, R., Minner, S., Bokemeyer, C., Sauter, G., Schlomm, T., & Trepel, M. (2013). High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. EUR J CANCER, 49(6), 1273-9. https://doi.org/10.1016/j.ejca.2012.11.035

Vancouver

Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. EUR J CANCER. 2013 Apr 1;49(6):1273-9. https://doi.org/10.1016/j.ejca.2012.11.035

Bibtex

@article{b2e320b51cb741228f80c703b6143873,
title = "High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer",
abstract = "Cell-mediated immunity may impact prostate cancer progression and has great therapeutic potential. Here, we investigated the clinical significance of the numeric density of regulatory T cells (Tregs) in prostate cancer as the presence of such cells in the tumour microenvironment has been linked to clinical outcome in other tumour entities. We detected Tregs by FOXP3 immunohistochemistry in 88.8% of 2002 prostate cancer specimens in tissue microarray format, the largest cohort so far in which Tregs have been quantified. The density of Tregs in tumour tissue was compared with pathological parameters and clinical outcome. The number of Tregs identified per 0.6mm tissue spot ranged from 1 to 10 in normal and 1 to 103 FOXP3+ cells in tumour samples. Prostate-specific antigen (PSA) recurrence-free survival was significantly reduced in patients with higher numbers of Tregs (p=0.0151). Further, a higher number of intratumoural FOXP3+ Tregs was associated with a more advanced tumour stage (p=0.0355) and higher Ki67 labelling index (p<0.0001). The tissue density of Tregs was unrelated to other clinical parameters such as spread to lymph nodes, preoperative PSA level and Gleason score. Our study suggests that the intratumoural presence of regulatory T cells may have substantial functional impact and may confer an adverse clinical course in prostate cancer.",
keywords = "Aged, Androgen Antagonists, Forkhead Transcription Factors, Humans, Immunity, Cellular, Immunohistochemistry, Kaplan-Meier Estimate, Ki-67 Antigen, Lymphocyte Count, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Outcome Assessment (Health Care), Preoperative Period, Prognosis, Proportional Hazards Models, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, T-Lymphocytes, Regulatory, Tissue Array Analysis",
author = "Anna Flammiger and Lars Weisbach and Hartwig Huland and Pierre Tennstedt and Ronald Simon and Sarah Minner and Carsten Bokemeyer and Guido Sauter and Thorsten Schlomm and Martin Trepel",
note = "Copyright {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",
year = "2013",
month = apr,
day = "1",
doi = "10.1016/j.ejca.2012.11.035",
language = "English",
volume = "49",
pages = "1273--9",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "6",

}

RIS

TY - JOUR

T1 - High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

AU - Flammiger, Anna

AU - Weisbach, Lars

AU - Huland, Hartwig

AU - Tennstedt, Pierre

AU - Simon, Ronald

AU - Minner, Sarah

AU - Bokemeyer, Carsten

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Trepel, Martin

N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Cell-mediated immunity may impact prostate cancer progression and has great therapeutic potential. Here, we investigated the clinical significance of the numeric density of regulatory T cells (Tregs) in prostate cancer as the presence of such cells in the tumour microenvironment has been linked to clinical outcome in other tumour entities. We detected Tregs by FOXP3 immunohistochemistry in 88.8% of 2002 prostate cancer specimens in tissue microarray format, the largest cohort so far in which Tregs have been quantified. The density of Tregs in tumour tissue was compared with pathological parameters and clinical outcome. The number of Tregs identified per 0.6mm tissue spot ranged from 1 to 10 in normal and 1 to 103 FOXP3+ cells in tumour samples. Prostate-specific antigen (PSA) recurrence-free survival was significantly reduced in patients with higher numbers of Tregs (p=0.0151). Further, a higher number of intratumoural FOXP3+ Tregs was associated with a more advanced tumour stage (p=0.0355) and higher Ki67 labelling index (p<0.0001). The tissue density of Tregs was unrelated to other clinical parameters such as spread to lymph nodes, preoperative PSA level and Gleason score. Our study suggests that the intratumoural presence of regulatory T cells may have substantial functional impact and may confer an adverse clinical course in prostate cancer.

AB - Cell-mediated immunity may impact prostate cancer progression and has great therapeutic potential. Here, we investigated the clinical significance of the numeric density of regulatory T cells (Tregs) in prostate cancer as the presence of such cells in the tumour microenvironment has been linked to clinical outcome in other tumour entities. We detected Tregs by FOXP3 immunohistochemistry in 88.8% of 2002 prostate cancer specimens in tissue microarray format, the largest cohort so far in which Tregs have been quantified. The density of Tregs in tumour tissue was compared with pathological parameters and clinical outcome. The number of Tregs identified per 0.6mm tissue spot ranged from 1 to 10 in normal and 1 to 103 FOXP3+ cells in tumour samples. Prostate-specific antigen (PSA) recurrence-free survival was significantly reduced in patients with higher numbers of Tregs (p=0.0151). Further, a higher number of intratumoural FOXP3+ Tregs was associated with a more advanced tumour stage (p=0.0355) and higher Ki67 labelling index (p<0.0001). The tissue density of Tregs was unrelated to other clinical parameters such as spread to lymph nodes, preoperative PSA level and Gleason score. Our study suggests that the intratumoural presence of regulatory T cells may have substantial functional impact and may confer an adverse clinical course in prostate cancer.

KW - Aged

KW - Androgen Antagonists

KW - Forkhead Transcription Factors

KW - Humans

KW - Immunity, Cellular

KW - Immunohistochemistry

KW - Kaplan-Meier Estimate

KW - Ki-67 Antigen

KW - Lymphocyte Count

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Outcome Assessment (Health Care)

KW - Preoperative Period

KW - Prognosis

KW - Proportional Hazards Models

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - T-Lymphocytes, Regulatory

KW - Tissue Array Analysis

U2 - 10.1016/j.ejca.2012.11.035

DO - 10.1016/j.ejca.2012.11.035

M3 - SCORING: Journal article

C2 - 23266046

VL - 49

SP - 1273

EP - 1279

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 6

ER -